Insights & Resources – COD Research

Medical Affairs

CT Quality Assurance

Clinical Services

Biometrics

Transforming Complexity into Success: A Large-Scale Global Phase III Biosimilar Dermatology Trial

Strategic Planning for Patient Recruitment

Pulmonary Disease Introduction: Prevalence, Causes, Prevention & Treatment

EMA
FDA
MHRA

Human medicines European public assessment report (EPAR): Iclusig, ponatinib, Date of authorisation: 01/07/2013, Revision: 30, Status: Authorised
Source: EMA Published on 2026-07-31
Sponsor guidance: New safety module on the annual safety report
Source: EMA Published on 2026-07-31
Fifth European Medicines Agency and Nuclear Medicines Europe bilateral meeting, Online, European Medicines Agency, Amsterdam, the Netherlands, 10 July 2026
Source: EMA Published on 2026-07-31
18th Industry Standing Group (ISG) meeting, Online, European Medicines Agency, Amsterdam, the Netherlands, from 21 September 2026, 09:00 (CEST) to 21 September 2026, 12:30 (CEST)
Source: EMA Published on 2026-07-31
First European Medicines Agency (EMA) and Active Pharmaceutical Ingredients Committee (APIC) bilateral meeting, European Medicines Agency, Amsterdam, the Netherlands, from 2 September 2026, 15:30 (CEST) to 2 September 2026, 17:30 (CEST)
Source: EMA Published on 2026-07-31
Human medicines European public assessment report (EPAR): Multaq, dronedarone, Date of authorisation: 25/11/2009, Revision: 23, Status: Authorised
Source: EMA Published on 2026-07-31

Read More